Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Finnish Foundation for Alcohol Studies |
---|---|
Information provided by: | Finnish Foundation for Alcohol Studies |
ClinicalTrials.gov Identifier: | NCT00325299 |
The primary purpose is to see if magnesium tablet supplementation will decrease elevated GGT enzyme activity in alcoholic patients immediately after they had been treated for alcohol withdrawal. The secondary aims are to find out whether supplementation decreases the activity of ASAT and ALAT enzymes, increases muscle strength, decreases blood pressure and decreases depressive symptoms among these patients.
Condition | Intervention | Phase |
---|---|---|
Alcohol-Induced Disorders |
Drug: Magnesium |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Magnesium After Alcohol Withdrawal Treatment |
Estimated Enrollment: | 178 |
Estimated Study Completion Date: | September 2005 |
Magnesium (Mg) deficiency is common among alcoholics. Animal studies have shown that magnesium deficiency aggravates the hepatic damage caused by alcohol. One study on chronic alcoholics suggested that magnesium supplementation over six weeks decreases abnormally high activities of three enzymes related to liver function: serum gamma-glutamyltransferase (GGT), aspartate-aminotransferase (ASAT) and alanine-aminotransferase (ALAT), and increases muscle strength [4]. These results were, however, significant at the 5% level only when a 1-sided test was applied. It seems that magnesium supplementation may improve liver recovery after a drinking bout, but the evidence is not yet strong enough to warrant clear recommendations for clinical practice. Magnesium deficiency may also be one of the symptoms of depression and may aggravate hypertension. The primary purpose of the present randomized, parallel group, double blind trial is to see if oral magnesium supplementation will decrease elevated GGT enzyme activity in alcoholic patients immediately after they had been treated for alcohol withdrawal. The secondary aims are to find out whether supplementation decreases the activity of ASAT and ALAT enzymes, increases muscle strength, decreases blood pressure and decreases depressive symptoms among these patients.
Ages Eligible for Study: | 20 Years to 64 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Finland | |
Finnish Foundation for Alcohol Studies | |
Helsinki, Finland, 00531 |
Principal Investigator: | Kari Poikolainen, Dr Med Sci | Finnish Foundation for Alcohol Studies |
Study ID Numbers: | FFAS-02 |
Study First Received: | May 11, 2006 |
Last Updated: | May 11, 2006 |
ClinicalTrials.gov Identifier: | NCT00325299 History of Changes |
Health Authority: | Finland: National Agency for Medicines |
Alcohol-Induced Disorders Substance-Related Disorders Disorders of Environmental Origin Alcohol-Related Disorders Ethanol |
Alcohol-Induced Disorders Substance-Related Disorders Disorders of Environmental Origin Alcohol-Related Disorders |